Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Alliance for Regenerative Medicine presentation, January 2012
7 slides from Lisata Therapeutics's conference presentation, Jan 6, 2012
Slide 1: A Paradigm Shift to Cell Therapy is Coming!
Alliance for Regenerative Medicine Robin Smith MD , MBA January 2012 Chairman & CEO A Paradigm Shift to Cell Therapy is Coming!
Slide 2: Capturing the Paradigm Shift to Cell Based Therapy
2 2 2 Capturing the Paradigm Shift to Cell Based Therapy
Slide 3: Cell Therapy Has Already Shown Promise Towards Unmet Therapeutic Needs
3 3 3 Cell Therapy Has Already Shown Promise Towards Unmet Therapeutic Needs • Provide exquisite control of glucose and insulin level (diabetes) • Immune tolerance regimens to combat autoimmunity • MS • Lupus • Osteoarthritis • GvHD • Solid organ rejection Reverse neurological damage Reset the immun
Slide 4: Value Creation in the Biotechnology Industry: Evolution of a Paradigm Shift
4 4 4 1980 1990 2000 1x 10x 100x 1000x 2010 Aggregate Industry Valuation Value Creation in the Biotechnology Industry Evolution of a Paradigm Shift Irrational Exuberance Reality Break - through Take Off First Recombinant Protein Therapeutic: Humulin ® First Recombinant Monoclonal Antibody: ORTHOCLON
Slide 5: Must Demonstrate Ability to Reduce Cost, Time and Risk of Cell Therapy Development
5 Must Demonstrate Ability to Reduce Cost, Time and Risk of Cell Therapy Development • Autologous vs. Allogeneic • Patient - specific vs Multi - patient Use • Sources of cells: Bone marrow derived, adipose, IPS, Embryonic, etc. • Fresh vs Cryopreserved • Shelf - life from sourcing to therapy (logist
Slide 6: Cell Therapy: Opportunities & Challenges in 2012
6 Cell Therapy : Opportunities & Challenges in 2012 • A paradigm s hift in cell t herapy is coming as evidenced by the number of products in later stage trials. • Hundreds of millions of dollars in federal funding has been allocated and distributed for regenerative medicine research (ARM, TATRC, CDM
Slide 7: NeoStem's Approach
7 NeoStem’s Approach Therapeutics Development Services Division Manufacturing & Family Banking • Autologous Stem Cell based Therapeutic for Cardiovascular Disease ( Amorcyte ) • T - Regulatory Program for Auto - Immune Disorders and GVHD & Solid Organ Rejection ( Athelos ) • Regenerative Medicine Pr
NeoStem — Alliance for Regenerative Medicine presentation, January 2012 on 6ix